Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00159471
Status:
TERMINATED
Last Update Posted:
2014-05-22
First Post:
2005-09-09
Brief Title:
Genes as Predictors of Response to Gemcitabine Docetaxel and Capecitabine GTX in Metastatic or Unresectable Pancreatic Cancer
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
A Pilot Trial of Germline Polymorphisms as Predictors of Response to Gemcitabine Docetaxel and Capecitabine GTX in Metastatic or Unresectable Pancreatic Cancer
Status:
TERMINATED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Insufficient Accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study for patients with advanced pancreatic cancer using the drugs gemcitabine docetaxel and capecitabine Gemcitabine is a drug that has been approved by the FDA Gemcitabine is been approved for treatment of cancer of the pancreas It is also approved for treatment of lung cancer in combination with another drug called cisplatin Docetaxel is a drug approved by the FDA Docetaxel is approved for treatment of breast and lung cancer Capecitabine is a drug approved by the FDA for treatment of cancer of the colon and rectum This study will measure the levels of certain substances in participants tumors These substances called genes which are the cells blueprint for these substances affect how peoples bodies react to the cancer drugs Genes will also be measured in participants blood The purpose of this study is to see if these substances can predict survival and response in patients receiving the study drugs In this study we wish to find out how long it takes for patients cancers to worsen and how long they survive after receiving the study drugs The side effects of the combination of gemcitabine docetaxel and capecitabine will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None